PT Saptausaha Gemilangindah Tbk (SAGE)
Jul 31, 2025 - SAGE was delisted (reason: acquired by SUPN)
8.68
-0.02 (-0.23%)
Inactive · Last trade price on Jul 30, 2025

Sage Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
18726---
Market Cap Growth
-99.99%-73.19%----
Enterprise Value
20827---
Last Close Price
0.000.000.00---
PE Ratio
-1455.3784.18---
PS Ratio
31.676.6618.29---
PB Ratio
1.050.391.40---
P/TBV Ratio
1.050.391.40---
EV/Sales Ratio
34.787.8218.93---
EV/EBITDA Ratio
-124.8071.77---
EV/EBIT Ratio
-168.4172.97---
Debt / Equity Ratio
0.080.080.050.070.090.07
Debt / EBITDA Ratio
-21.262.420.691.71-
Asset Turnover
0.030.050.080.130.100.02
Inventory Turnover
0.060.120.210.390.300.06
Quick Ratio
0.190.460.950.040.040.02
Current Ratio
4.825.154.720.330.360.32
Return on Equity (ROE)
-1.09%0.03%2.30%9.62%4.33%-5.67%
Return on Assets (ROA)
-0.47%0.15%1.21%3.02%1.42%-1.02%
Return on Invested Capital (ROIC)
-0.50%0.16%1.62%6.30%3.15%-1.67%
Return on Capital Employed (ROCE)
-0.30%1.90%9.60%4.80%-
Earnings Yield
-1.05%0.07%1.19%---
Buyback Yield / Dilution
12.62%0.00%-25.06%--180.45%-281.98%
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q